|
Section 1: Baseline Knowledge
|
| Modes of transmission - adults |
3.3 |
3.8 |
0.0083 |
| Modes of transmission - children |
2.905 |
3.737 |
0.0060 |
| Clinical course - adults |
2.619 |
3.7 |
0.0016 |
| Clinical course - children |
2.278 |
3.5 |
0.0004 |
| Signs and symptoms - adults |
3.19 |
3.905 |
0.0014 |
| Signs and symptoms - children |
2.6 |
3.65 |
0.0043 |
| Use of manuals –positive prevention& HIV |
3.25 |
3.75 |
0.0247 |
| Use of Department of Health stationery |
2.8 |
3.789 |
0.0003 |
| Core differences between adults & children |
2.263 |
3.524 |
0.0013 |
|
Section 2: Before ARVs
|
| HIV counselling and testing - adults |
3.25 |
3.85 |
0.0008 |
| HIV counselling and testing - children |
2.111 |
3.714 |
<0.0001 |
| Diagnosis - adults |
3 |
3.8 |
0.0003 |
| Diagnosis - children |
2 |
3.55 |
<0.0001 |
| Staging - adults |
3.3 |
3.905 |
0.0053 |
| Staging - children |
1.8 |
3.619 |
<0.0001 |
| Body Mass Index calculation and management |
3.2 |
3.952 |
<0.0001 |
| Paediatric weight chart and management |
1.789 |
3.474 |
<0.0001 |
| TB screening - adults |
3.476 |
3.857 |
0.1279 |
| TB screening - children |
2.476 |
3.476 |
0.0046 |
| Pap smears and HIV |
2.95 |
3.8 |
0.0007 |
| Common opportunistic infections - adults |
2.952 |
3.762 |
0.0013 |
| Common opportunistic infections - children |
2.1 |
3.381 |
0.0003 |
| TB diagnosis and management - adults |
3.05 |
3.571 |
0.0799 |
| Drug side effects |
2.905 |
3.824 |
0.0187 |
| Cotrimoxazole use - adults |
3.429 |
3.714 |
0.1654 |
| Cotrimoxazole use - children |
2.048 |
3.81 |
<0.0001 |
|
Section 3: Starting ARVs
|
| Eligibility criteria to start - adults |
2.857 |
3.667 |
0.0029 |
| Eligibility criteria to start - children |
1.65 |
3.429 |
<0.0001 |
| Fast-tracking criteria |
2.762 |
3.75 |
0.0001 |
| Blood result interpretation - adults |
2.5 |
3.762 |
0.0003 |
| Working withcreatinine clearance |
2.1 |
3.905 |
<0.0001 |
| Individual ART contra-indications |
2.35 |
3.81 |
0.0004 |
| Pre-start adherence counseling |
2.55 |
3.7 |
0.0003 |
| Department of Health1st line regimen - adults (ARVs, doses, side effects) |
3 |
3.714 |
0.0870 |
| Department of Health1st line regimen – children (ARVs, doses, side effects) |
1.65 |
3.476 |
<0.0001 |
| Prescribing w concurrent illnesses - TB, epilepsy, hypertension, diabetes |
1.857 |
3.75 |
<0.0001 |
| Normal course on ARVs |
2.737 |
3.905 |
<0.0001 |
| Side effects and their management: |
|
|
|
| Skin, haematology, liver, kidney, psychiatric |
2.143 |
3.6 |
0.0010 |
| Recognition of side effects |
2.667 |
3.429 |
0.0530 |
| Understanding IRIS |
2.35 |
3.571 |
0.0031 |
| Long-term side effects |
2.053 |
3.667 |
0.0002 |
| Failing regimen - warning signs |
2.4 |
3.667 |
0.0002 |
| Diagnosis - clinical, immunological, virological |
1.842 |
3.619 |
<0.0001 |
| When to refer |
2.333 |
3.857 |
<0.0001 |
|
Section 4: HIV & Pregnancy
|
| Family planning |
3.095 |
3.762 |
0.0012 |
| Wanting to fall pregnant |
2.19 |
3.9 |
<0.0001 |
| During pregnancy |
2.571 |
3.7144 |
0.0005 |
| After pregnancy - mother |
2.35 |
3.762 |
0.0003 |
| After pregnancy - child |
2.1 |
3.5 |
0.0006 |
|
Section 5: Post-exposure Prophylaxis
|
| Non-drug management and administration |
2.05 |
3.762 |
<0.0001 |
| Drug regimen and indications |
2.15 |
3.65 |
0.0006 |
|
Section 6: General
|
| Management of weight loss |
2.7 |
3.571 |
0.0066 |
| Routine clinical examination |
2.438 |
3.667 |
0.0001 |
| Cardiac failure |
1.667 |
3.118 |
0.0005 |
| Enlarged liver |
1.81 |
3.313 |
0.0009 |
| Neck stiffness |
2.15 |
3.5 |
0.0009 |
| Procedures for lactate testing |
1.571 |
3.2 |
0.0001 |
| Understanding the register |
2.111 |
3.167 |
0.0186 |
